Acurx pharmaceuticals, inc.ACXP.US Overview
ACXP Overall Performance
ACXP AI Analysis & Strategy
ACXP Recent Performance
-2.70%
Acurx pharmaceuticals, inc.
0.81%
Avg of Sector
-1.14%
S&P500
ACXP PowerScanner
ACXP Key Information
ACXP Valuation Metrics
ACXP Earnings Table
ACXP Profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.